Related Experiment Video

Updated: Jun 14, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.6K

Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer

Chongyu Wang1, Pinchao Fan2, Qingqing Wang3

  • 1Department of Medicine, Xinglin College, Nantong University, Nantong 226007, Jiangsu, China.

Cancer Treatment Reviews
|August 31, 2024
PubMed

Insights

Triple-negative breast cancer (TNBC) treatments can cause cardiovascular toxicity (CTR-CVT). This review details TNBC therapies, their cardiotoxic effects, and monitoring strategies for better patient outcomes.

Area of Science:

  • Oncology
  • Cardiology
  • Cardio-Oncology

Background:

  • Triple-negative breast cancer (TNBC) is a heterogeneous subtype with poor prognosis.
  • Cancer therapy-related cardiovascular toxicity (CTR-CVT) significantly impacts TNBC survivors.
  • Cardio-oncology is emerging to manage cardiovascular risks in cancer patients.

Purpose of the Study:

  • To review the molecular subtyping and therapeutic landscape of TNBC.
  • To introduce monitoring approaches for CTR-CVT.
  • To elaborate on cardiotoxicities associated with anti-TNBC treatments.

Main Methods:

  • Literature review of TNBC molecular subtypes and therapies.
  • Analysis of cardiotoxic effects from various treatments (chemotherapy, surgery, radiotherapy, immunotherapy).
  • Discussion of CTR-CVT monitoring strategies.

Main Results:

  • TNBC classification and treatment evolution are presented.
  • Cardiotoxicities from anthracyclines, surgery, anesthetics, radiotherapy, and immunotherapy are detailed.
  • Monitoring methods for CTR-CVT are outlined.

Conclusions:

  • Understanding CTR-CVT is crucial for TNBC survivors.
  • Integrated cardio-oncology care is essential for managing treatment-related cardiovascular risks.
  • Future research directions include AI and traditional Chinese medicine in cardio-oncology.
Keywords:
Cancer therapy-related cardiovascular toxicityCardio-oncologyMultidisciplinary teamTreatment-related adverse eventTriple-negative breast cancerWhole-course management

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

17.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493